<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types
Background Image

3D Ex Vivo Patient Tissue Platform

Moving Immuno-Oncology Models Closer to the Clinic

Despite advances in both 3D in vitro human cell-based models and in vivo animal models, 97% of oncology drugs that enter clinical trials fail to receive regulatory approval. To overcome this poor approval rate, we need patient-relevant translational systems that better mimic the heterogeneity and molecular/genetic complexity of human tumors to:

  • Understand drug effects on the native tumor microenvironment (TME)
  • Gain more accurate insights beyond general cell viability (i.e. CTG)
  • Evaluate immuno-oncology (I/O) drugs including immune checkpoint inhibitors (ICI) with endogenous immune cells

The 3D ex vivo patient tissue platform is a highly translatable screening assay for evaluating monotherapy and combination drug responses in patient tumors with endogenous immune cell populations intact. Includes the option to use in co-culture with autologous immune cells.

A Unique 3D Ex Vivo Patient Tissue Platform


Contact us to discuss your 3D Ex Vivo Patient Tissue project

Features Applications Readouts

Advancement Over Traditional Models

In recent years, the TME has been shown to play a crucial role in cancer progression and metastasis as well as treatment response. However, there has been a lack of research models that accurately represent the human TME. Challenges associated with traditional models include:

  • In vitro assays, such as 2D cell lines, lack the complexity and heterogeneity of patient-derived tumors and its TME.
  • In vivo models, such as PDX and GEMM, are more complex to develop and have lower throughput. 

The 3D ex vivo patient tissue platform provides an alternative approach by keeping the complexity of the tumor (3D assay) and including the patient autologous TME into the assay.

Preserving Patient Tissue Biology

Make better informed decisions about progressing compounds/therapeutic candidates into the clinic with the most clinically relevant ex vivo patient tissue platform.

Comparison of Models

poor (x), medium (~), high (√)

Attributes 2D cultures Organoids In vivo Ex vivo
Physiological complexity X ~
Throughput X ~
Translatability to the clinic X ~ ~

Contact us to discuss your 3D Ex Vivo Patient Tissue project


  • Physiologically relevant 3D models. Understand immuno-oncology therapeutic effects on fresh patient tissue with native TME in 3D which is the most physiologically relevant preclinical environment. Preserves native TME with endogenous immune cells, fibroblasts, and other stromal components. From patients to assay plate within 24 hours.
  • Multiple readouts. Select from a variety of readouts including high content imaging for efficient combination and dosing regimen evaluations, and flow cytometry for in depth evaluation of the immune population.
  • Co-culture with autologous PBMCs available. Test your compound efficacy in an enhanced TME.
  • Reliable, reproducible data. Tumor killing and immune cell proliferation are accurately measured via phenotypic analysis to support important R&D decisions.
  • Customizable 384-well plate format. Patient-specific plate: 50-300 patient tumor tissues directly seeded in hydrogel matrix in 384-well format.


Ex vivo testing protocols established for a wide range of solid tumors representing the complexity of the TME and preserving patient tumor biology.

  • Mono- and combination therapy assessment, including ICI evaluation in vitro:

NSCLC Patient Samples Response to ICI Correlates With Clinical Data

Heatmap showcasing the differential response of 25 NSCLC patient samples to a set of SoC treatments including pembrolizumab and ipilimumab.

  • Late-stage preclinical candidate evaluation

Cytokine Analysis Confirms HCI Results

a) Ex vivo tumor tissue from NSCLC patient responded strongly to SEA and moderately to CD3/CD28 beads and pembrolizumab treatment (6 days).
b) NSCLC tumoroid in medium only and SEA conditions (DAPI: nuclei; TRITC: actin) c) HCI response measurements were confirmed by cytokine analysis
at various timepoints (2, 4, and 6 days). The increase in IFNgamma, Granzyme B, and IL-2 upon IO treatments is supporting the
immune-mediated killing mechanism

  • Potential for identifying responder/non-responder profiles

Differential Responses to SoC Drugs in Breast Cancer Patient Tissue Samples

a) Example images of OBS004 response to different treatment conditions. b) Patient-specific sensitivity (4 breast cancer samples) to a
6-point concentration curve of 5-FU and doxorubicin c) Heatmap illustrating SoC response to a set of standard of care drugs.

  • Immune response testing in patient tumors with enhance TME
  • Potential for selection of indication for clinical trials


Multiple readouts available including:

  • High Content Imaging: functional assay assessing phenotypic effects of the (immune)-oncology compounds on ex vivo patient cultures in 3D
  • FACS: to gain insights on immune niche composition of the primary samples. Up to 10 marker panels can be tailor-made specifically to your project needs.  
  • IHC: to confirm tumor, stromal and immune content in the initial samples as well as to analyze specific target expression
  • Cytokine analysis: to gain an in depth cytokine, which can be indicative of cellular processes before these take effect in functional readout.
  • Sequencing: to address genetic and transcriptional profiles of the primary ex vivo samples.

Our ex vivo patient tissue platform is one of several high-content imaging-based screening assays offered. These include:

Contact us to discuss your 3D Ex Vivo Patient Tissue project.


Discuss Your 3D Ex Vivo Patient Tissue Project

Tell us how we can help